Year |
Citation |
Score |
2020 |
Zakaria HM, Wilkinson BM, Pennington Z, Saadeh YS, Lau D, Chandra A, Ahmed AK, Macki M, Anand SK, Abouelleil MA, Fateh JA, Rick JW, Morshed RA, Deng H, Chen KY, ... ... Kalkanis S, et al. Sarcopenia as a Prognostic Factor for 90-Day and Overall Mortality in Patients Undergoing Spine Surgery for Metastatic Tumors: A Multicenter Retrospective Cohort Study. Neurosurgery. PMID 32592483 DOI: 10.1093/Neuros/Nyaa245 |
0.319 |
|
2020 |
Wells M, Asmaro KP, Sabedot TS, Mosella MS, Malta, PharmD TM, Nelson K, Snyder J, deCarvalho A, Mukherjee A, Chitale D, Robin A, Rosenblum ML, Mikkelsen T, Poisson L, ... ... Kalkanis S, et al. OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.542 |
0.371 |
|
2020 |
Wells M, Asmaro K, Rock J, Sabedot T, Mosella M, Malta T, Nelson K, Snyder J, Kalkanis S, Castro AV, Noushmehr H. Abstract A11: Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A11 |
0.359 |
|
2020 |
Sabedot T, Malta T, Snyder J, Nelson K, Wells M, deCarvalho A, Mukherjee A, Chitale D, Mosella M, Asmaro K, Robin A, Rosenblum M, Mikkelsen T, Rock J, Poisson L, ... ... Kalkanis S, et al. Abstract A10: Glioma cell-free DNA methylation marker for diagnosis and monitoring Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A10 |
0.354 |
|
2020 |
Sabedot TS, Malta TM, She R, Snyder J, Walbert T, Lee I, Kalkanis S, Ewing J, Castro A, Noushmehr H. Abstract 781: Methylation-based liquid biopsy of meningioma primary and recurrent samples Cancer Research. 80: 781-781. DOI: 10.1158/1538-7445.Am2020-781 |
0.389 |
|
2018 |
de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, Laird PW, Wiznerowicz M, Iavarone A, Snyder J, deCarvalho A, Sanborn Z, McDonald KL, Friedman WA, Tirapelli D, ... ... Kalkanis S, et al. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Reports. 23: 637-651. PMID 29642018 DOI: 10.1016/J.Celrep.2018.03.107 |
0.371 |
|
2018 |
Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085 |
0.363 |
|
2018 |
Sabedot T, deCarvalho A, Poisson L, Snyder J, Walbert T, Lee I, Kalkanis S, Berman B, Noushmehr H. GENE-13. GENOMIC FUNCTIONAL ENHANCERS DEFINE POTENTIAL TUMORIGENESIS OF G-CIMP-LOW (IDH-MUTANT ASTROCYTOMA) TUMORS INDEPENDENT OF PROMOTER METHYLATION Neuro-Oncology. 20: vi105-vi105. DOI: 10.1093/Neuonc/Noy148.439 |
0.312 |
|
2018 |
Mosella M, Malta T, Sabedot T, Felicella M, Aho T, Poisson L, deCarvalho A, Snyder J, Lee I, Kalkanis S, Walbert T, Noushmehr H, Rock J, Castro AV. GENE-07. GENOMIC ENHANCER METHYLATION IS ASSOCIATED WITH BIOLOGICAL AND CLINICAL FEATURES IN PITUITARY TUMORS Neuro-Oncology. 20: vi104-vi104. DOI: 10.1093/Neuonc/Noy148.434 |
0.321 |
|
2018 |
Accomando W, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Vogelbaum M, Elder J, Piccioni D, Walbert T, Hogan D, Diago O, Gammon D, Haghighi A, et al. ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7. DOI: 10.1093/Neuonc/Noy148.021 |
0.304 |
|
2017 |
Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE Neuro-Oncology. 19: vi30-vi31. DOI: 10.1093/Neuonc/Nox168.116 |
0.351 |
|
2017 |
Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aguirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 19: vi265-vi266. DOI: 10.1093/Neuonc/Nox168.1089 |
0.372 |
|
2017 |
Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, et al. ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT Neuro-Oncology. 19: vi26-vi26. DOI: 10.1093/Neuonc/Nox168.099 |
0.371 |
|
2016 |
Katakowski M, Pikula E, Kalkanis S, Chopp M. Abstract 4641: Bone marrow stromal cells frustrate temozolomide treatment of glioblastoma Cancer Research. 76: 4641-4641. DOI: 10.1158/1538-7445.Am2016-4641 |
0.304 |
|
2016 |
Ostertag D, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Das A, Jolly D, Gruber H, Vogelbaum M. ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.082 |
0.323 |
|
2016 |
Cloughesy T, Walbert T, Bota D, Vogelbaum M, Liau L, Ostertag D, Jolly D, Gruber H, Yang L, Shorr J, Kalkanis S. ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 18: vi17-vi17. DOI: 10.1093/Neuonc/Now212.067 |
0.304 |
|
2015 |
Ostertag D, Hogan D, Vogelbaum M, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen C, Niethammer A, Chu A, Jolly D, Gruber H, Cloughesy T. GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE Neuro-Oncology. 17: v98.2-v98. DOI: 10.1093/Neuonc/Nov215.30 |
0.382 |
|
2014 |
Mazaris P, Hong X, Altshuler D, Schultz L, Poisson LM, Jain R, Mikkelsen T, Rosenblum M, Kalkanis S. Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital. Clinical Neurology and Neurosurgery. 120: 103-12. PMID 24731587 DOI: 10.1016/J.Clineuro.2014.03.001 |
0.36 |
|
2014 |
Cloughesy TF, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Liau LM, Chen CC, Bloomfield S, Piccioni D, Chiocca EA, Foltz G, Robbins JM, Ostertag D, Jolly DJ, et al. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 16: v110-v111. DOI: 10.1093/Neuonc/Nou258.4 |
0.394 |
|
2014 |
Kalkanis S, Jolly DJ, Pertschuk D, Ostertag D, Robbins JM, Huang TT, Gruber H, Mikkelsen T. At-29Intravenous Administration Of Toca 511 In Patients With Recurrent Glioblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.29 |
0.341 |
|
2014 |
Rosenblum ML, Robin A, Walbert T, Mikkelsen T, Kalkanis S, Rosenblum M. Brain Tumor Care Through The Patient'S Eyes — The Value Of A Comprehensive Brain Tumor Center Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou209.31 |
0.307 |
|
2012 |
Robbins JR, Ryu S, Kalkanis S, Cogan C, Rock J, Movsas B, Kim JH, Rosenblum M. Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery. 71: 937-43. PMID 22806080 DOI: 10.1227/Neu.0B013E31826909F2 |
0.322 |
|
2012 |
Gates M, Alsaidi M, Kalkanis S. Surgical treatment of solitary brain metastases. Progress in Neurological Surgery. 25: 74-81. PMID 22236669 DOI: 10.1159/000331178 |
0.342 |
|
2010 |
deCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S, Mikkelsen T. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (Dayton, Ohio). 28: 181-90. PMID 19937755 DOI: 10.1002/Stem.264 |
0.305 |
|
2009 |
Rosenblum ML, Kalkanis S, Goldberg W, Rock J, Mikkelsen T, Remer S, Whitehouse S, Nerenz D. Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care. Journal of Neuro-Oncology. 92: 241-51. PMID 19357952 DOI: 10.1007/S11060-009-9828-1 |
0.336 |
|
2007 |
Barker F, Kalkanis S, McKenna M, Poe D, Nadol J, Ojemann R. Long-Term Radiologic Follow-Up of Tumor Remnants after Subtotal Resection of Acoustic Neuromas Skull Base Surgery. 16. DOI: 10.1055/S-2006-958304 |
0.318 |
|
Show low-probability matches. |